Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters








Database
Language
Publication year range
1.
Sci Rep ; 11(1): 23462, 2021 12 06.
Article in English | MEDLINE | ID: mdl-34873203

ABSTRACT

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. The search included studies through 11-May-2020. Selection criteria included studies evaluating efficacy and safety outcomes of medical cannabinoids (tetrahydrocannabinol, cannabidiol and other cannabis derivatives) versus control in children, independently assessed by two reviewers. Eight studies were included, all of which are randomized controlled trials. Cannabidiol is associated with 50% reduction in seizures rate (Relative Risk (RR) = 1.69, 95% CI [1.20-2.36]) and caregiver global impression of change (Median Estimated difference = (- 1), 95%CI [- 1.39-(- 0.60)]) in Dravet syndrome, compared to placebo. While cannabidiol was associated with a reduction in reported seizure events (RR = 0.59, 95% CI [0.36-0.97]), no association was found in products contained also tetrahydrocannabinol (RR = 1.35, 95% CI [0.46-4.03]). Higher dose of cannabidiol was associated with decreased appetite (RR = 2.40, 95% CI [1.39-4.15]). A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. In conclusion, cannabidiol is associated with clinical improvement in Dravet syndrome. However, cannabidiol is also associated with decreased appetite. Adverse mental events were reported as well, however, more research should be performed to assess well this outcome.


Subject(s)
Cannabinoids/adverse effects , Cannabinoids/therapeutic use , Medical Marijuana/adverse effects , Medical Marijuana/therapeutic use , Animals , Child , Epilepsies, Myoclonic/drug therapy , Humans
2.
Nucleic Acids Res ; 39(13): 5704-14, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21450806

ABSTRACT

Human nuclear RNase P is required for transcription and processing of tRNA. This catalytic RNP has an H1 RNA moiety associated with ten distinct protein subunits. Five (Rpp20, Rpp21, Rpp25, Rpp29 and Pop5) out of eight of these protein subunits, prepared in refolded recombinant forms, bind to H1 RNA in vitro. Rpp20 and Rpp25 bind jointly to H1 RNA, even though each protein can interact independently with this transcript. Nuclease footprinting analysis reveals that Rpp20 and Rpp25 recognize overlapping regions in the P2 and P3 domains of H1 RNA. Rpp21 and Rpp29, which are sufficient for reconstitution of the endonucleolytic activity, bind to separate regions in the catalytic domain of H1 RNA. Common themes and discrepancies in the RNA-protein interactions between human nuclear RNase P and its related yeast and archaeal counterparts provide a rationale for the assembly of the fully active form of this enzyme.


Subject(s)
Protein Subunits/metabolism , RNA/metabolism , Ribonuclease P/metabolism , Autoantigens/genetics , Autoantigens/metabolism , Base Sequence , Binding Sites , Humans , Magnesium/pharmacology , Molecular Sequence Data , Protein Folding , Protein Subunits/chemistry , Protein Subunits/genetics , RNA/chemistry , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Ribonuclease P/chemistry , Ribonuclease P/genetics , Ribonucleases/genetics , Ribonucleases/metabolism , Ribonucleoproteins/genetics , Ribonucleoproteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL